150 related articles for article (PubMed ID: 23892904)
21. Toxicity and outcomes in combined modality treatment of head and neck squamous cell carcinoma: cisplatin versus cetuximab.
Ye AY; Hay JH; Laskin JJ; Wu JS; Ho CC
J Cancer Res Ther; 2013; 9(4):607-12. PubMed ID: 24518704
[TBL] [Abstract][Full Text] [Related]
22. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
[TBL] [Abstract][Full Text] [Related]
23. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
Prosnitz RG; Yao B; Farrell CL; Clough R; Brizel DM
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1087-95. PubMed ID: 15752888
[TBL] [Abstract][Full Text] [Related]
24. Importance of the treatment package time in surgery and postoperative radiation therapy for squamous carcinoma of the head and neck.
Rosenthal DI; Liu L; Lee JH; Vapiwala N; Chalian AA; Weinstein GS; Chilian I; Weber RS; Machtay M
Head Neck; 2002 Feb; 24(2):115-26. PubMed ID: 11891941
[TBL] [Abstract][Full Text] [Related]
25. Impact of average weekly dose of radiation during radiotherapy alone or chemoradiotherapy in head and neck cancer.
Dragovic AF; Bonner JA; Spencer SA; Nabell LM; Carroll WR; Caudell JJ
Head Neck; 2011 Nov; 33(11):1551-6. PubMed ID: 21990218
[TBL] [Abstract][Full Text] [Related]
26. Risk factors for osteoradionecrosis of the jaw in patients with head and neck squamous cell carcinoma.
Kubota H; Miyawaki D; Mukumoto N; Ishihara T; Matsumura M; Hasegawa T; Akashi M; Kiyota N; Shinomiya H; Teshima M; Nibu KI; Sasaki R
Radiat Oncol; 2021 Jan; 16(1):1. PubMed ID: 33402192
[TBL] [Abstract][Full Text] [Related]
27. Intensity-modulated radiotherapy or volumetric-modulated arc therapy in patients with head and neck cancer: Focus on salivary glands dosimetry.
Vallard A; Guy JB; Mengue Ndong S; Vial N; Rivoirard R; Auberdiac P; Méry B; Langrand-Escure J; Espenel S; Moncharmont C; Ben Mrad M; Diao P; Goyet D; Magné N
Head Neck; 2016 Jul; 38(7):1028-34. PubMed ID: 26855006
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial: concurrent radio-chemotherapy with weekly docetaxel for advanced squamous cell carcinoma of head and neck.
Biete Solà A; Marruecos Querol J; Calvo Manuel FA; Verger Fransoy E; Rovirosa Casino A; Grau de Castro JJ; de Las Heras González M; Ramos Aguerri A; Palacios Eito A; Veiras Candal C; Solano López MV
Clin Transl Oncol; 2007 Apr; 9(4):244-50. PubMed ID: 17462977
[TBL] [Abstract][Full Text] [Related]
29. Brainstem dose is associated with patient-reported acute fatigue in head and neck cancer radiation therapy.
Ferris MJ; Zhong J; Switchenko JM; Higgins KA; Cassidy RJ; McDonald MW; Eaton BR; Patel KR; Steuer CE; Baddour HM; Miller AH; Bruner DW; Xiao C; Beitler JJ
Radiother Oncol; 2018 Jan; 126(1):100-106. PubMed ID: 28826628
[TBL] [Abstract][Full Text] [Related]
30. Effect of radiotherapy on psychiatric disorder in patients with head and neck cancer.
Unal D; Orhan O; Ozsoy SD; Besirli A; Eroglu C; Kaplan B
Indian J Cancer; 2016; 53(1):162-5. PubMed ID: 27146770
[TBL] [Abstract][Full Text] [Related]
31. The use of carboplatin and paclitaxel with daily radiotherapy in patients with locally advanced squamous cell carcinomas of the head and neck.
Suntharalingam M; Haas ML; Conley BA; Egorin MJ; Levy S; Sivasailam S; Herman JM; Jacobs MC; Gray WC; Ord RA; Aisner JA; Van Echo DA
Int J Radiat Oncol Biol Phys; 2000 Apr; 47(1):49-56. PubMed ID: 10758304
[TBL] [Abstract][Full Text] [Related]
32. The impact of tumor volume and radiotherapy dose on outcome in previously irradiated recurrent squamous cell carcinoma of the head and neck treated with stereotactic body radiation therapy.
Rwigema JC; Heron DE; Ferris RL; Andrade RS; Gibson MK; Yang Y; Ozhasoglu C; Argiris AE; Grandis JR; Burton SA
Am J Clin Oncol; 2011 Aug; 34(4):372-9. PubMed ID: 20859194
[TBL] [Abstract][Full Text] [Related]
33. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003.
Fu KK; Pajak TF; Trotti A; Jones CU; Spencer SA; Phillips TL; Garden AS; Ridge JA; Cooper JS; Ang KK
Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):7-16. PubMed ID: 10924966
[TBL] [Abstract][Full Text] [Related]
34. Reirradiation of Recurrent and Second Primary Head and Neck Cancer With Proton Therapy.
McDonald MW; Zolali-Meybodi O; Lehnert SJ; Estabrook NC; Liu Y; Cohen-Gadol AA; Moore MG
Int J Radiat Oncol Biol Phys; 2016 Nov; 96(4):808-819. PubMed ID: 27788954
[TBL] [Abstract][Full Text] [Related]
35. Recurrences near base of skull after IMRT for head-and-neck cancer: implications for target delineation in high neck and for parotid gland sparing.
Eisbruch A; Marsh LH; Dawson LA; Bradford CR; Teknos TN; Chepeha DB; Worden FP; Urba S; Lin A; Schipper MJ; Wolf GT
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):28-42. PubMed ID: 15093896
[TBL] [Abstract][Full Text] [Related]
36. Radiation-induced hypothyroidism after treatment of head and neck cancer.
Feen Rønjom M
Dan Med J; 2016 Mar; 63(3):. PubMed ID: 26931197
[TBL] [Abstract][Full Text] [Related]
37. Reirradiation of Head and Neck Cancers With Intensity Modulated Radiation Therapy: Outcomes and Analyses.
Takiar V; Garden AS; Ma D; Morrison WH; Edson M; Zafereo ME; Gunn GB; Fuller CD; Beadle B; Frank SJ; William WN; Kies M; El-Naggar AK; Weber R; Rosenthal DI; Phan J
Int J Radiat Oncol Biol Phys; 2016 Jul; 95(4):1117-31. PubMed ID: 27354127
[TBL] [Abstract][Full Text] [Related]
38. IAEA-HypoX. A randomized multicenter study of the hypoxic radiosensitizer nimorazole concomitant with accelerated radiotherapy in head and neck squamous cell carcinoma.
Hassan Metwally MA; Ali R; Kuddu M; Shouman T; Strojan P; Iqbal K; Prasad R; Grau C; Overgaard J
Radiother Oncol; 2015 Jul; 116(1):15-20. PubMed ID: 25913070
[TBL] [Abstract][Full Text] [Related]
39. Development of Distress During a Radiotherapy Course for Head-and-neck Cancer.
Rades D; Delikanli C; Yu NY; Janssen S
Anticancer Res; 2023 Sep; 43(9):4149-4153. PubMed ID: 37648327
[TBL] [Abstract][Full Text] [Related]
40. Toxicity of head-and-neck radiation therapy in human immunodeficiency virus-positive patients.
Sanfilippo NJ; Mitchell J; Grew D; DeLacure M
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1375-9. PubMed ID: 20097488
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
